Inhibitors of vapor space polymerization

By using composition inhibitors that stabilize nitrogen oxygen radicals and phenylenediamine in the vapor space of the distillation column, the spontaneous polymerization of ethylenically unsaturated monomers in the vapor space is solved, significantly reducing polymer formation and equipment Risk of damage.

CN118946541APending Publication Date: 2024-11-12ECOLAB USA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031681.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-01
Filing Date
2023-03-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the vapor space area of ​​the distillation column, ethylenically unsaturated monomers are prone to spontaneous polymerization, resulting in the formation of unwanted polymers. The existing inhibitors are mainly limited to liquid flow, which cannot effectively prevent polymerization in the vapor space, resulting in equipment damage. and safety hazards.

Method used

Using a composition comprising a first inhibitor compound that stabilizes the nitrogen oxygen radical and a second inhibitor compound of phenylenediamine, the composition includes a compound of a specific structure such as 1- oxy-2,2,6,6-tetramethylpiperidin-4-ol and 1,4-phenylenediamine, concentrations between 0.01% and 80%, and molar ratios range from 100:1 to 1:100.

Benefits of technology

It effectively prevents monomer polymerization in the vapor space, reduces the formation of dirt polymers, and reduces equipment damage and safety risks, especially in the presence of high temperatures and oxidants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946541A_ABST
    Figure CN118946541A_ABST
Patent Text Reader

Abstract

Inhibitor compositions for reducing undesired polymerization in the vapor space during purification of reactive vinyl monomers are provided. These polymerization inhibitor compositions comprise at least a first inhibitor compound having a stable nitroxide radical and a second inhibitor comprising a phenylenediamine. Methods of inhibiting polymerization of monomers in a vapor space using the compositions of the present disclosure are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to compositions comprising a blend of polymerization inhibitors and methods of using the compositions to inhibit unwanted polymerization in the vapor space region. More specifically, the present disclosure relates to compositions comprising at least one compound having a stable nitroxide radical and a phenylenediamine that can be used to inhibit the polymerization of ethylenically unsaturated monomers in the vapor space region. Background Art

[0002] Ethylenically unsaturated monomers are typically manufactured in a three-stage process consisting of (i) reaction, (ii) recovery, and (iii) purification. Distillation operations at high temperatures typically involve recovery and purification stages. The process includes fractionation of the monomers. At the top of the distillation tower, the purified monomer vapors are condensed into a liquid pool and then transferred to a storage facility. Some of the condensed monomer stream flows down the tower. In the vapor space region of the distillation tower, the liquid monomer pool may generate spontaneous or peroxide-initiated free radicals. Current polymer inhibitor technology is limited to the liquid stream at the bottom of the process tower. Inhibitors are typically non-volatile, so they are confined to the bottom of the distillation tower, and no inhibitor reaches the highly reactive monomer pool in the vapor space portion. For conventional inhibitors, the collected monomers are not treated to reduce unwanted polymerization. Therefore, reactive monomers are undesirably polymerized by free radical polymerization, particularly at elevated temperatures or when in contact with rust on the surface of process equipment such as distillation tower plates.

[0003] The polymerization is particularly vigorous in the presence of polymerization initiators such as organic peroxides, which are commonly found in recycle streams previously exposed to atmospheric oxygen. Conventional polymerization inhibitors such as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (HTEMPO) and 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl (OTEMPO) are generally effective. The premature polymerization of these monomers is usually controlled by metering the polymerization inhibitor directly into the liquid hydrocarbon stream to reduce the premature polymerization of the monomers. However, these polymerization inhibitors (HTEMPO and OTEMPO) are not volatile. In the art, the process is accelerated when the liquid monomer condenses on the trays, which are much higher than the bulk liquid treated with non-volatile polymerization inhibitors. The problem becomes very serious if the trays are rusted or when there is residual polymer in cracks and corners. Equally important, due to the Norris-Trommsdorf effect, pre-existing polymers in equipment cracks, dead legs and liquid monomer retention pools can lead to rapid accumulation of fouling polymers. Growing polymer fouling can cause mechanical damage due to accelerated polymerization and can release large amounts of heat, which can cause fire or explosion. Complete suppression of tray corrosion or complete removal of polymer from hard-to-reach locations in purification columns means that it is difficult to prevent unwanted polymerization in the vapor space. Summary of the invention

[0004] A method for inhibiting polymerization of monomers in the vapor space portion of a distillation column is provided. The method comprises adding a composition as described herein to the monomers. The composition comprises a first inhibitor compound containing a stable nitroxide free radical and a second inhibitor compound containing a phenylenediamine.

[0005] In some aspects, the first inhibitor compound has Formula (I):

[0006]

[0007] Where R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0008] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Tridecyloxy-2,2,6,6-tetramethylpiperidin -1-oxy; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6- tetramethylpiperidin-1-oxy; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy; and any combination thereof.

[0009] In some aspects, the first inhibitor is a compound of Formula III:

[0010]

[0011] wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0012] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.

[0013] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0014]

[0015] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0016] In some aspects, X1 and X2 are independently C1-C 22 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.

[0017] In some aspects, X1 and X2 are independently C1-C 10 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.

[0018] In some aspects, X1 and X2 are independently C1-C5 alkyl or phenyl, wherein the alkyl and phenyl are optionally substituted with one or more C1-C5 alkyl groups. 22 Alkyl or aryl substituted.

[0019] In some aspects, the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.

[0020] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 80 wt %.

[0021] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 50 wt %.

[0022] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100.

[0023] In some aspects, the composition further comprises an organic solvent.

[0024] In some aspects, the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.

[0025] A method for inhibiting monomer polymerization is provided. The method comprises adding a composition to a process stream in a monomer purification process. The composition comprises a first inhibitor compound containing a stable nitroxide free radical and a second inhibitor compound containing a phenylenediamine.

[0026] In some aspects, the process stream includes a monomer.

[0027] In some aspects, the process stream further comprises one or more additional components selected from the group consisting of an acid, an organic solvent, and water.

[0028] In some aspects, the monomer is an ethylenically unsaturated monomer.

[0029] In some aspects, the composition is added to the process stream such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0030] In some aspects, the composition is added to the process stream such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0031] In some aspects, the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.

[0032] The above has been a fairly extensive overview of the features and technical advantages of the present disclosure so that the following specific description may be better understood. Other features and advantages of the present disclosure will be described below, which constitute the subject matter of the claims of this application. It will be appreciated by those skilled in the art that the disclosed concepts and specific aspects may be readily used as a basis for modifying or designing other aspects for achieving the same purpose of the present disclosure. It will also be appreciated by those skilled in the art that such disclosure of equivalent aspects does not depart from the spirit and scope of the present disclosure as described in the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Specific embodiments of the present invention are described below in detail with reference to the accompanying drawings.

[0034] Figure 1 Vapor space polymerization inhibitors of various formulations are shown. DETAILED DESCRIPTION

[0035] Various aspects of the present disclosure are described below. The relationship and function of various aspects of the elements can be better understood by reference to the following detailed description. However, various aspects are not limited to those explicitly described herein, and it should be understood that in some cases, details that are unnecessary for understanding various aspects disclosed herein, such as, for example, conventional synthesis and / or preparation, may have been omitted.

[0036] During extractive distillation of reactive conjugated diene monomers, vapor space polymerization may occur, resulting in unwanted fouling. A need exists for polymerization inhibitors that can effectively prevent vapor space polymerization. The compositions and methods disclosed herein can prevent or reduce emulsion polymerization.

[0037] As used herein, "vapor space" refers to the portion of a distillation apparatus that is typically in contact with vapor rather than liquid process streams.

[0038] A method for inhibiting monomer polymerization is provided. The method comprises adding a composition to a process stream in a monomer purification process. The composition comprises a first inhibitor compound containing a stable nitroxide free radical and a second inhibitor compound containing a phenylenediamine.

[0039] The present disclosure relates to compositions including blends of polymerization inhibitors and methods of using the same to inhibit polymerization of ethylenically unsaturated monomers. The polymerization inhibitor compositions of the present disclosure include at least one compound having thermally and chemically stable nitroxide free radicals and phenylenediamine. The polymerization inhibitor composition may be a blend of multiple components, including components other than the above-mentioned compounds having stable nitroxide free radicals and phenylenediamine.

[0040] In the presence of polymerizable monomers, a "polymerization inhibitor" inhibits the polymerization of these monomers during the induction time under shutdown conditions. After the induction time has elapsed after the polymerization inhibitor is completely consumed, polymer formation occurs at the same rate as in the complete absence of the polymerization inhibitor.

[0041] Polymerization inhibitors and polymerization retarders are generally considered "anti-polymerization agents," which are compounds that can inhibit or reduce the formation of polymers from one or more free radically polymerizable compounds.

[0042] The term "fouling" refers to the formation of polymers, prepolymers, oligomers and / or other materials that are insoluble in the stream and / or precipitate out of the stream and deposit on the equipment under the operating conditions of the equipment. In turn, the inhibitor compositions of the present disclosure may be referred to as "antifouling" because they inhibit or reduce the formation of fouling polymers.

[0043] Compositions of the present disclosure

[0044] The present disclosure relates to a composition for inhibiting the polymerization of monomers, wherein the composition comprises a first inhibitor compound having a stable nitroxide free radical and a second inhibitor compound phenylenediamine. In some aspects, the composition used herein is particularly useful for preventing vapor space polymerization in a distillation tower. In some aspects, the composition is used to inhibit the polymerization of monomers, wherein the monomer is an ethylenically unsaturated monomer. For example, the composition of the present disclosure can be used to inhibit the polymerization of ethylenically unsaturated monomers, including but not limited to vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, acrylic acid, (meth) acrylic acid, and combinations thereof.

[0045] In some aspects, the first inhibitor compound having a stable nitroxide radical is a compound of formula (I):

[0046]

[0047] Where R1 is H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22Alkylene aryl, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0048] The term "aryl" refers to monocyclic, bicyclic (fused) and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term "aryl" can be used interchangeably with the term "aryl ring".

[0049] In certain aspects, R1 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl and aryl substitution.

[0050] In some aspects, R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0051] In some aspects, R1 is H. In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22In some aspects, R1 is aryl, wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C1-C 22 Alkylene aryl, wherein the aryl group is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(C1-C 22 In some aspects, R1 is -C(O)(C1-C 12 In some aspects, R1 is -C(O)(C1-C6 alkyl). In some aspects, R1 is -C(O)(methyl). In some aspects, R1 is -C(O)(ethyl). In some aspects, R1 is -C(O)(propyl). In some aspects, R1 is -C(O)(butyl). In some aspects, R1 is -C(O)(C1-C6 alkyl). 22 In some aspects, R1 is -C(O)(C1-C 22 In some aspects, R1 is -C(O)(C1-C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(aryl), wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(C1-C 22 alkylene aryl), wherein the aryl group is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0052] Examples of compounds of formula (I) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol -1-oxy; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-tridecyloxy-2,2,6,6-tetramethyl Piperidin-1-oxyl; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2 , 6,6-tetramethylpiperidin-1-oxy; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy.

[0053] In other aspects, the first inhibitor compound has formula (II):

[0054]

[0055] Wherein R2 is selected from H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0056] In certain aspects, R2 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0057] In some aspects, R2 is H. In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is aryl, wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C1-C 22 Alkylene, wherein the alkylene is optionally substituted by aryl, the aryl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 In some aspects, R2 is -C(O)(C1-C 12In some aspects, R2 is -C(O)(C1-C6 alkyl). In some aspects, R2 is -C(O)(methyl). In some aspects, R2 is -C(O)(ethyl). In some aspects, R2 is -C(O)(propyl). In some aspects, R2 is -C(O)(butyl). In some aspects, R2 is -C(O)(C1-C6 alkyl). 22 In some aspects, R2 is -C(O)(C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(aryl), wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 alkylene), wherein the alkylene is optionally substituted by an aryl group, the aryl group is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0058] In some aspects, the compound of formula (II) is 2,2,6,6-tetramethylpiperidin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1 -ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin -1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6 ,6-tetramethylpiperidin-1-ol; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol.

[0059] In some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are the same. For example, in some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are each independently -C(O)(C1-C 22 In certain aspects, the compositions of the present disclosure comprise a first inhibitor compound and a second inhibitor compound of formula (I) and (II), respectively, wherein R1 and R2 are different.

[0060] The compounds of formula (II) with hydroxylamine disclosed in the present invention have advantages over the corresponding nitrogen oxides (compounds of formula (I)), such as the ability to provide additional polymerization inhibition, which will be explained more fully below. The general synthetic route of hydroxylamine to produce nitrogen oxides is to reduce its corresponding nitrogen oxide with a reducing agent as follows:

[0061]

[0062] Hydroxylamines of nitroxides have the potential to provide additional polymerization inhibition compared to the corresponding nitroxides in the presence of carbon-centered and oxygen-centered free radical initiators. This is explained as follows:

[0063]

[0064] Due to its weak NO-H bond in the compound, the hydroxylamine of nitrogen oxide is an excellent hydrogen donor, so it is an effective antioxidant. As an antioxidant, the hydroxylamine of nitroxide free radical easily reacts with oxygen-centered free radicals (such as peroxide free radicals), and it is converted into its corresponding nitroxide free radical. Nitrogen oxides are generally considered to be the most effective inhibitors because they have excellent inhibition ability by removing carbon-centered free radicals at a rate that almost controls diffusion. This rate is several orders of magnitude faster than phenolic compounds. However, their kinetic superiority is not always favorable. For example, when oxygen-centered free radicals exist as the main free radicals, it may lose its superiority. Another problem related to nitrogen oxides is its consumption by non-inhibition and undesirable reactions with process stream components or other inhibitor additives. Therefore, high nitrogen oxide inhibitor dosages are usually required for a given inhibition efficacy, making their use economically unattractive or even unfeasible.

[0065] In essence, when both oxygen-centered free radicals and carbon-centered free radicals are present, each hydroxylamine of the nitroxide is equivalent to a hydrogen donor plus a nitroxide anti-polymerizer, which is an attractive motivation provided by the hydroxylamine of the nitroxide. That is, one hydroxylamine of the nitroxide can eliminate one oxygen-centered free radical and one carbon-centered free radical, while the nitroxide can only eliminate the carbon-centered free radical.

[0066] In some aspects, the first inhibitor is a compound of Formula III:

[0067]

[0068] wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0069] In some aspects, R3 is -O. In some aspects, R3 is -OH.

[0070] In some aspects, R4 is optionally replaced by one or more C1-C 22 Alkyl or aryl substituted C1-C 22 In some aspects, R4 is optionally replaced by one or more C1-C 22 Alkyl or aryl substituted aryl.

[0071] Examples of compounds of formula (iii) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; or 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate.

[0072] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0073]

[0074] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0075] In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV). In some aspects, the second inhibitor compound is a phenylenediamine of formula (V).

[0076] Examples of phenylenediamines include, but are not limited to, 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, and N,N′-diphenyl-1,4-phenylenediamine.

[0077] In some aspects, the composition comprises 2,2',6,6'-tetramethylpiperidinyl-1-oxyl and an alkyl-substituted 1,4-phenylenediamine.

[0078] In some aspects, the composition consists essentially of the first inhibitor compound and the second inhibitor compound. In other aspects, the composition consists of an organic solvent, a first inhibitor, and a second inhibitor.

[0079] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.

[0080] For example, in some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %, or about 80 wt %.

[0081] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 50% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 40% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 30% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 20% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 10% by weight.

[0082] For example, in some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, or about 50 wt %.

[0083] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 90:1 to about 1:90. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 80:1 to about 1:80. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 70:1 to about 1:70. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 60:1 to about 1:60. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 50:1 to about 1:50. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 40:1 to about 1:40. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 30:1 to about 1:30. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 20:1 to about 1:20. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 10:1 to about 1: 10. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is about 1:1.

[0084] In some aspects, the composition further comprises one or more additional compounds selected from the group consisting of: 2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethylpiperidin-1-ol; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-oxo-2 , 2,6,6-tetramethylpiperidin-1-ol; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol; and bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl)oxalate. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes oxalic acid bis((2,2,6,6-tetramethylpiperidin-1-oxy)-4-yl) ester.

[0085] The composition can also optionally include one or more organic solvents. It will be appreciated by those of ordinary skill in the art that there are many organic solvents compatible with the composition of the present disclosure. For example, in some aspects, one or more organic solvents are selected from vinyl acetate, dimethyl phthalate, dimethyl formamide, toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes dimethyl phthalate. In some aspects, the composition also includes dimethyl formamide. In some aspects, the composition also includes toluene. In some aspects, the composition also includes xylene. In some aspects, the composition also includes high aromatic naphtha. In some aspects, the composition also includes acetonitrile.

[0086] In some aspects, the composition also includes one or more ethylenically unsaturated monomers. It will be appreciated by those of ordinary skill in the art that there are many ethylenically unsaturated monomers compatible with the compositions of the present disclosure. For example, in some aspects, one or more ethylenically unsaturated monomers are selected from vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth) acrylic acid and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes acrylonitrile. In some aspects, the composition also includes acrylate. In some aspects, the composition also includes methacrylate. In some aspects, the composition also includes 1,3-butadiene. In some aspects, the composition also includes styrene. In some aspects, the composition also includes isoprene. In some aspects, the composition also includes (meth) acrylic acid.

[0087] The compositions of the present disclosure are stable and are useful polymerization inhibitors even under acidic conditions. Therefore, the compositions of the present disclosure can be used to inhibit premature polymerization of monomers in manufacturing processes, particularly those carried out under acidic conditions. For example, the compositions of the present disclosure can be used to prevent the polymerization of acrylates, which can include but are not limited to acrylonitrile, acrylic acid, methacrylic acid and its esters, and vinyl acetate.

[0088] In some aspects, the compositions disclosed herein do not include 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. In some aspects, the compositions disclosed herein do not include 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl. In some aspects, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl are not added to ethylenically unsaturated monomers.

[0089] The present disclosure also relates to methods of inhibiting polymerization of monomers, comprising adding a composition of the present disclosure to the monomers. In some aspects, an effective amount of a composition of the present disclosure is added to the monomers, wherein an effective amount is any amount sufficient to inhibit polymerization of the monomers.

[0090] In some aspects, the monomer is an ethylenically unsaturated monomer. In some aspects, the monomer is an ethylenically unsaturated monomer selected from the following items: vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, (meth) acrylic acid and combinations thereof. In some aspects, the method disclosed herein can be used to inhibit the polymerization of vinyl acetate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylonitrile. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of methacrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of 1,3-butadiene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of styrene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of isoprene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylic acid. In some aspects, the method disclosed herein can be used to inhibit the polymerization of (meth) acrylic acid.

[0091] The composition of the present disclosure can be added to the fluid manually or automatically. The composition can also be added continuously and / or intermittently. Automatic addition can be accomplished by using a chemical dosing pump. The chemical dosing pump can be programmed to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid at certain time intervals. In optional aspects, the chemical dosing pump can be manually controlled to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid. Adding the currently disclosed polymerization inhibitor composition to the monomer will thus inhibit the polymerization of the monomer.

[0092] In some aspects, the monomer is provided as a pure liquid. In other aspects, the monomer is provided in a solution, hereinafter referred to as a "monomer solution".

[0093] In some aspects, the monomer solution also includes one or more additional components selected from acid, organic solvent, water and combination thereof. For example, in some aspects, the monomer solution includes one or more organic solvents selected from the following items: vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, ethyl toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combination thereof. In some aspects, the monomer solution includes one or more acids selected from hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, perchloric acid, formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, acetic acid, caprylic acid, undecanoic acid, lauric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid and suberic acid. In some aspects, the monomer solution includes water.

[0094] In some aspects, the pH of the monomer solution is from about 1 to about 7. In some aspects, the pH of the monomer solution is from about 1 to about 6. In some aspects, the pH of the monomer solution is from about 2 to about 6. In some aspects, the pH of the monomer solution is from about 3 to about 6. In some aspects, the pH of the monomer solution is from about 4 to about 6. In some aspects, the pH of the monomer solution is from about 5 to about 6.

[0095] In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0096] In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0097] The method of the present disclosure can be used to inhibit premature polymerization of monomers during the extraction process. During the extraction process, a solvent is used to separate the components. The polarity difference between the extraction solvent and the hydrocarbon layer leads to emulsion formation, thereby increasing the risk of emulsion polymerization.

[0098] The methods of the present disclosure can also be used to prevent premature polymerization of styrene during the manufacturing and purification processes.

[0099] The method disclosed herein can also be used in butadiene extraction processes. This utility stems from the equilibrium partition coefficient between the polar organic phase and the organic phase.

[0100] In some aspects, the compositions disclosed herein are used for distillation purification of olefins. For example, the composition can be added to a process stream before entering a distillation unit, or the composition can be added to a process stream in a distillation unit.

[0101] Example

[0102] Example 1 :

[0103] Various formulations were screened for vapor space polymerization inhibition. Volatile nitroxides and alkyl-substituted 1,4-phenylenediamines were found to exhibit synergistic effects and outperform commercial vapor space polymerization inhibitors such as dialkylhydroxylamines and nitroxide HTEMPO.

[0104] Isoprene was passed through an alumina column to remove 4-tert-butylcatechol (TBC). About 100 ppm of active inhibitor was added to isoprene without TBC (about 125 g). The solution was purged with nitrogen. Several popcorn seeds weighing about 0.15 g were added to the top of the sample kit. The tube was sealed and heated to 80°C and stirred at a regulated stirring rate of 250 rpm for 3 days. The added weight in the kit reflects the inhibitor performance on popcorn formation.

[0105] Figure 1 The combination of volatile nitroxides and alkyl-substituted 1,4-phenylenediamines showed a synergistic effect. Figure 1 In the above, the ester of HTEMPO refers to 4-acetoxy-2,2'6,6'-tetramethylpiperidinyl-1-oxyl; 8550-36-2 refers to 15 wt% 4-acetoxy-2,2'6,6'-tetramethylpiperidinyl-1-hydroxyl and 5 wt% di-sec-butyl-4,4'-phenylenediamine; DEHA is N,N'-diethylhydroxylamine; and PDA is di-sec-butyl-4,4'-phenylenediamine.

[0106] All compositions and methods disclosed and claimed herein can be prepared and performed according to the present disclosure without undue experimentation. Although the present invention can be embodied in many different forms, specific preferred embodiments of the present invention are described in detail herein. The present disclosure is an illustration of the principles of the present invention and is not intended to limit the present invention to the specific embodiments shown. In addition, unless explicitly stated to the contrary, the use of the term "one / kind" is intended to include "at least one / at least one" or "one or more / one or more". For example, "inhibitor" is intended to include "at least one inhibitor" or "one or more inhibitors".

[0107] Any range given in absolute terms or in approximate terms is intended to cover both, and any definition used herein is intended to be clarifying and not restrictive. Although the numerical ranges and parameters describing the broad scope of the present invention are approximate, the numerical values ​​described in the specific embodiments are reported as accurately as possible. However, any numerical value inherently contains certain errors caused by the standard deviation found in its corresponding experimental measurement. In addition, all ranges disclosed herein are understood to cover any and all subranges (including all fractional values ​​and overall values) contained therein.

[0108] Any composition disclosed herein may comprise, consist of, or consist essentially of any element, component, and / or ingredient disclosed herein, or any combination of two or more of the elements, components, or ingredients disclosed herein.

[0109] Any method disclosed herein may comprise, consist of, or consist essentially of any method step disclosed herein or any combination of two or more of the method steps disclosed herein.

[0110] The transitional phrase "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional unrecited elements, components, ingredients, and / or method steps.

[0111] The transitional phrase "consisting of" excludes any element, component, ingredient and / or method step not specified in the claim.

[0112] The transition phrase "consisting essentially of" limits the scope of a claim to the specified elements, components, ingredients and / or steps, and those that do not materially affect the basic and novel characteristics of the claimed invention.

[0113] As used herein, the term "about" means that the recited value is within the standard deviation found in their respective testing measurements, and if those errors are not determinable, "about" may mean, for example, within 5% of the recited value.

[0114] In addition, the present invention encompasses any and all possible combinations of some or all of the various aspects described herein. It should also be understood that the various changes and modifications made to the current preferred aspects described herein are obvious to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without reducing its expected advantages. Therefore, the appended claims are intended to cover such changes and modifications.

Claims

1. A method for inhibiting vapor space monomer polymerization, the method comprising: adding the composition to a process stream in a monomer purification process, wherein the composition comprises a first inhibitor compound comprising a stable nitroxide radical; and a second inhibitor compound comprising a phenylenediamine.

2. The method of claim 1, wherein the first inhibitor compound has formula (I): Where R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

3. The method according to claim 1 or claim 2, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexyloxy 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Tridecyloxy-2,2, 6,6-tetramethylpiperidin-1-oxyl; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2, 6,6-tetramethylpiperidin-1-oxyl; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxyl; and any combination thereof.

4. The method of claim 1, wherein the first inhibitor is a compound of formula III: wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

5. The method of claim 1 or claim 4, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.

6. The method according to any one of claims 1 to 5, wherein the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V): Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

7. The method according to any one of claims 1 to 6, wherein the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.

8. The method of any one of claims 1 to 7, wherein the first inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 80 wt%.

9. The method of any one of claims 1 to 8, wherein the second inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 50 wt%.

10. The method of any one of claims 1 to 9, wherein the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:

100.

11. The method according to any one of claims 1 to 10, wherein the composition further comprises an organic solvent.

12. The process of any one of claims 1 to 11, wherein the process stream further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.

13. The method according to any one of claims 1 to 12, wherein the process stream further comprises one or more additional components selected from the group consisting of: an acid, an organic solvent and water.

14. The method of any one of claims 1 to 13, wherein the composition is added to the process stream such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

15. The method of any one of claims 1 to 14, wherein the composition is added to the process stream such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.